Response to the randomized trial of recombinant human erythropoietin in critically ill patients [1]

Critical Care Medicine

Volumn 35, Issue 6, 2007, Pages 1632-

  Belova, Eva ^a   Kanna, Balavenkatesh ^a,b  

^a Lincoln Hospital   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

APACHE; ARTIFICIAL VENTILATION; CRITICAL ILLNESS; DRUG EFFICACY; HEALTH STATUS; HUMAN; IRON OVERLOAD; LETTER; PRIORITY JOURNAL; RANDOMIZATION; SAMPLE SIZE; STATISTICAL SIGNIFICANCE;

AGED; ANEMIA; APACHE; CRITICAL ILLNESS; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; IRON;

EID: 34249306586     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000266837.49803.D0     Document Type: Letter

References (5)

1. Silver M, Corwin M, Bazan A, et al: Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: A randomized, double-blind, placebo-controlled trial. Crit Care Med 2006; 34: 2310-2316
2. Woolard RH, Carty K, Wirtz P, et al: Research fundamentals: Follow-up of subjects in clinical trials: Addressing subject attrition. Acad Emerg Med 2004; 11:859-866
3. Altman DG, Bland JM: Statistics notes: How to randomize. BMJ 1999; 319:703-704
4. Ho KM, Dobb GJ, Knuiman M, et al: A comparison of admission and worst 24-hour Acute Physiology and Chronic Health Evaluation II scores in predicting hospital mortality: A retrospective cohort study. Crit Care 2006; 10:R4
5. Piagnerelli M, Rapotec A, Cotton F, et al: Iron administration in the critically iii. Semin Hematol 2006; 43(4 Suppl 6):S23-S27